<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728622</url>
  </required_header>
  <id_info>
    <org_study_id>NSGO-OC-0101</org_study_id>
    <nct_id>NCT02728622</nct_id>
  </id_info>
  <brief_title>Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane</brief_title>
  <official_title>A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society of Gynaecological Oncology - Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Society of Gynaecological Oncology - Clinical Trials Unit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study of chemotherapy versus hormonal treatment in patients with ovarian cancer&#xD;
      resistant or refractory to platinum and taxane.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with platinum-resistant invasive epithelial ovarian, fallopian tube or peritoneal&#xD;
      cancer will be randomized 1:2 to either hormonal treatment with Tamoxifen 40 mg daily or&#xD;
      chemotherapy of investigator's choice (weekly paclitaxel given as an 1 hour infusion of&#xD;
      paclitaxel 80 mg/m2 or pegylated liposomal doxorubicin 40 mg/m2 given every 4 weeks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality-adjusted survival</measure>
    <time_frame>through completion of study, on average 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>through completion of study, on average 3 months</time_frame>
    <description>time to progressive disease or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>through completion of study, on average 1 year</time_frame>
    <description>time to death of any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Cancer of the Fallopian Tube</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 40 mg is given orally once daily until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>endocrine treatment</description>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Paclitaxel or pegylated liposomal doxorubicin</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>paclitaxel</other_name>
    <other_name>pegylated liposomal doxorubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with invasive epithelial ovarian, fallopian tube or peritoneal cancer, being&#xD;
             resistant to treatment with platinum and a taxane, either given in combination or&#xD;
             sequentially.&#xD;
&#xD;
          -  Patients with clinical progression during or within 6 months after end of treatment&#xD;
             for primary disease or relapse.&#xD;
&#xD;
          -  Patients with stable disease after 6 courses of chemotherapy for primary disease or&#xD;
             relapse if further treatment is indicated.&#xD;
&#xD;
          -  Patients with doubling of s-CA 125 to at least 70 IU/Ml within 3 months after end of&#xD;
             treatment for primary disease or relapse.&#xD;
&#xD;
          -  Age must be at least 18 years.&#xD;
&#xD;
          -  Performance status must be 0-2 (WHO/ECOG, appendix 1).&#xD;
&#xD;
          -  Informed consent given according to ICH/EU GCP guidelines and local or national laws&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis&#xD;
&#xD;
          -  Bilirubin greater than 2 x UNL (upper normal limits), white blood cell count below 3.0&#xD;
             x 109/L, neutrophil count below 1.5 x 109/L, platelets count below 100 x 109/L.&#xD;
&#xD;
          -  Active infection or other serious underlying medical condition which might prevent the&#xD;
             patient from receiving treatment or to be followed.&#xD;
&#xD;
          -  Pregnant, lactating, or child bearing potential patients without adequate&#xD;
             contraception&#xD;
&#xD;
          -  Previous treatment with Tamoxifen.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar B Kristensen, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>The Norwegian Radium Hospital, Oslo University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>platinum-resistant</keyword>
  <keyword>endocrine treatment</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>tamoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

